The short answer: a new Nature Medicine study followed 8,127 UK women who started a GLP-1 through an online program, and the authors say their results resembled the early months of the big clinical trials. The more useful finding is how the program worked. Labs came before the first prescription, weight was verified on video, a clinician reviewed every refill, and doses went up only when a clinician decided they should. The study has real limits: no comparison group, a self-pay population, six months of follow-up, and a program co-run by companies whose staff co-wrote the paper.
Who ran it
The program was SheMed, a UK online weight-loss service for women. Prescribing was done by UK-registered clinicians at eMed Healthcare UK, a Care Quality Commission-registered provider, with "a pooled team of 25 general practitioners, with support from clinical pharmacists and advanced nurse practitioners," according to the paper. Women joined between November 2024 and January 2025, and 99.8% started tirzepatide.
The analysis was funded by a grant from The Chicago Community Trust, administered through University College London, and the paper says the funder had no role in the study. The lead author, John Deanfield of UCL, reports consulting fees from eMed, among other disclosures. Two authors are employees of SheMed and eMed, which the paper says "co-operated the digital program evaluated in this study."
The care model, element by element
The authors set their program apart from "transactional prescribing services with limited additional features." Here is what it required, from the paper and its supplementary methods, each paired with a question you can ask any online prescriber.
| What the program did | The detail | What to ask your provider |
|---|---|---|
| Labs before the first prescription | A home blood test (£49, refunded if ineligible) was required. Of 16,121 people who passed initial screening, 4,025 were not included only because they didn't complete it, and 308 more were excluded after a clinician reviewed their results or history. | Will a clinician look at recent lab results before prescribing? |
| Verified identity and weight | A trained, nonmedical "proctor" checked photo ID and watched a baseline weigh-in over live video. | How do you confirm my weight and identity? |
| A refill is a clinical decision | Women had to complete a monthly questionnaire and "undergo clinical review before medication refills were approved." | Does a clinician review my care before each refill? |
| Doses go up only when a clinician decides | Clinicians were advised not to raise the dose if a woman had lost 2 kg or more in the past month or reported moderate or severe side effects, "with a focus on achieving the lowest effective dose." The average tirzepatide dose at six months was 9.5 mg. | Who decides when my dose changes, and on what basis? |
| A plan for side effects | Everyone got an over-the-counter symptom kit and dietary guidance at the start. Reports of severe or concerning symptoms "triggered clinical review within 24 h." Among women with side effects, 5.0% of those who used the kit stopped treatment, compared with 7.4% of those who didn't. | What happens if I have side effects, and how fast does a clinician respond? |
| Pregnancy checks every month | Pregnancy was asked about at each refill. Eleven women reported pregnancy and all stopped treatment immediately. | Do you check for pregnancy and contraception during treatment? |
| Weekly check-ins | Women were encouraged to join weekly video check-ins with proctors, who confirmed weight and doses taken. Proctors "did not provide clinical assessment or treatment advice," but could escalate concerns. | Who checks on me between prescriptions, and what can they escalate? |
| Your own doctor knows | GP details were required, and clinical information was shared with each woman's GP, the authors told reviewers in the peer-review file. | Will you share my treatment with my regular doctor if I ask? |
| Repeat labs | A second home blood test was sent at six months. | Will you recheck labs during treatment? |
What happened
Retention was high: 91.4% were still on treatment at six months, and 8.6% stopped. Most women (62.7%) reported at least one side effect; of those, 7.7% rated the worst one severe. The authors report "no serious treatment-related adverse events." Average weight loss was 15.5% of starting weight, which the authors call consistent with the early phase of the major trials.
What the study does not show
- It cannot prove the care model caused anything. There was no comparison group, so we can't tell how much came from the medication, the structure, or the women who chose to join.
- The women paid, and the price was discounted. The provider partly subsidized fees during the study. A reviewer noted the "exact cost/discount" was "not revealed," and the authors agree the pricing "may not be a sustainable, scalable commercial structure."
- It was a narrow group. All women, 88% white, mostly without serious health problems, in the UK. The authors say the results "should not be generalized to populations who require GLP-1RA therapy owing to greater obesity-related complications."
- Six months is short. The authors call for longer follow-up on durability and regain after stopping.
- Some data were missing or self-reported. Medical history wasn't checked against health records, blood pressure wasn't collected, and 79.6% completed the repeat blood test.
- Eating-disorder screening isn't spelled out. The listed exclusions include "active substance misuse or severe psychiatric instability," but the paper doesn't describe a specific eating-disorder screen.
The reviewers pushed on several of these points. One first recommended rejection and wrote that "conclusions frequently overreach," and in the next round recommended minor revision. Another, in the final round, wrote that the limitations "significantly impact the quality of the paper and the replicability in terms of wider rollout." As of October 17, 2026, we found no independent news coverage or expert reaction yet; the published peer-review file is the best outside commentary so far.
Why this matters in the US
US online prescribing varies widely. In a Yale "secret shopper" study published in JAMA, a researcher received a GLP-1 prescription from 45 of 49 websites, and only 55.1% asked about eating disorders, Healio reported. This UK program shows a more structured version is possible at scale. It doesn't show that every element is necessary, and it was tested on one group of women in one country.
Where Temi fits
At Temi, a licensed physician reviews every request, and a renewal is never automatic: each one is a new request with a fresh decision from the physician. We charge for the clinical review, not for prescribing, so a decision not to prescribe is part of the service. You choose the pharmacy. Temi handles GLP-1s and everyday medications: everyday refills are $15 per renewal and a new prescription review is $79, both $0 with Temi Care ($449 a year). We serve patients in Arizona, California, Colorado, Delaware, Florida, Michigan, Missouri, New York, North Carolina, Ohio, Pennsylvania, Texas, and Wisconsin.
The paper, supplementary methods, and peer-review file were read on October 17, 2026.




